Cargando…

Real-World Use of Tedizolid Phosphate for 28 Days or More: A Case Series Describing Tolerability and Clinical Success

Tedizolid has activity against Gram-positive pathogens as well as Mycobacterium spp and Nocardia spp. Real-world evidence supporting long-term tolerability and clinical success of tedizolid is lacking. Prolonged tedizolid therapy (median, 188 days; interquartile range, 62–493 days) appeared to be we...

Descripción completa

Detalles Bibliográficos
Autores principales:	Morrisette, Taylor, Molina, Kyle C, Da Silva, Beatriz, Mueller, Scott W, Damioli, Laura, Krsak, Martin, Miller, Matthew A, Fish, Douglas N
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9126493/ https://www.ncbi.nlm.nih.gov/pubmed/35615295 http://dx.doi.org/10.1093/ofid/ofac028

Ejemplares similares

2287. Real-world Use of Tedizolid Phosphate: A Case Series of Long-Term Tolerability
por: Morrisette, Taylor, et al.
Publicado: (2019)

Tedizolid Phosphate: a Next-Generation Oxazolidinone
por: Rybak, Jeffrey M., et al.
Publicado: (2015)

Real-Life Evidence for Tedizolid Phosphate in the Treatment of Cellulitis and Wound Infections: A Case Series
por: Shlyapnikov, Sergey, et al.
Publicado: (2018)

Stability of crushed tedizolid phosphate tablets for nasogastric tube administration
por: Kennedy, G, et al.
Publicado: (2015)

Stability of Crushed Tedizolid Phosphate Tablets for Nasogastric Tube Administration
por: Kennedy, Gerard, et al.
Publicado: (2015)

Development and Evaluation of Chitosan Nanoparticles for Ocular Delivery of Tedizolid Phosphate
por: Kalam, Mohd Abul, et al.
Publicado: (2022)

Intracellular activity of tedizolid phosphate and ACH-702 versus Mycobacterium tuberculosis infected macrophages
por: Molina-Torres, Carmen A, et al.
Publicado: (2014)

Potential role of tedizolid phosphate in the treatment of acute bacterial skin infections
por: Urbina, Olatz, et al.
Publicado: (2013)

Safety and tolerability of tedizolid as oral treatment for bone and joint infections
por: Miller, Loren G., et al.
Publicado: (2023)

Pharmacokinetics and Pharmacodynamics of Tedizolid
por: Iqbal, Khalid, et al.
Publicado: (2022)

306. Safety and Tolerability of Tedizolid as Oral Treatment for Bone and Joint Infections
por: Launer, Bryn, et al.
Publicado: (2018)

Perspectives of Positively Charged Nanocrystals of Tedizolid Phosphate as a Topical Ocular Application in Rabbits
por: Alshememry, Abdullah, et al.
Publicado: (2022)

2421. Tedizolid Is Well-Tolerated Among Patients Receiving Prolonged Treatment Courses
por: Marini, Rachel V, et al.
Publicado: (2018)

Tedizolid clearance by in vitro continuous renal replacement therapy model
por: Lewis, SJ, et al.
Publicado: (2015)

Profile of tedizolid phosphate and its potential in the treatment of acute bacterial skin and skin structure infections
por: Hall, Ronald G, et al.
Publicado: (2015)

Red Blood Cell Membrane-Camouflaged Tedizolid Phosphate-Loaded PLGA Nanoparticles for Bacterial-Infection Therapy
por: Wu, Xinyi, et al.
Publicado: (2021)

Pharmacokinetic/Pharmacodynamic Analysis of Tedizolid Phosphate Compared to Linezolid for the Treatment of Infections Caused by Gram-Positive Bacteria
por: Rodríguez-Gascón, Alicia, et al.
Publicado: (2021)

Fabrication and Characterization of Tedizolid Phosphate Nanocrystals for Topical Ocular Application: Improved Solubilization and In Vitro Drug Release
por: Kalam, Mohd Abul, et al.
Publicado: (2022)

In vitro Susceptibility of Nontuberculous Mycobacteria to Tedizolid
por: Zhang, Huiyun, et al.
Publicado: (2022)

Tolerance of Prolonged Oral Tedizolid for Prosthetic Joint Infections: Results of a Multicentre Prospective Study
por: Senneville, Eric, et al.
Publicado: (2020)

Response: No More “28 Days and You’re Cured”
por: Cohen, Allan J., et al.
Publicado: (2007)

Tedizolid: new data and experiences for clinical practice
por: Lletí, Miguel Salavert, et al.
Publicado: (2021)

Tedizolid phosphate for the treatment of acute bacterial skin and skin-structure infections: an evidence-based review of its place in therapy
por: Bassetti, Matteo, et al.
Publicado: (2019)

A Mycobacterium tuberculosis-Infected Patient Who Could Not Tolerate Oral Intake Successfully Treated Using an Intravenous Tedizolid-Containing Regimen
por: Karaushi, Haruka, et al.
Publicado: (2022)

Response to Mahatanan and Kang: It's Complicated
por: Molina, Kyle C, et al.
Publicado: (2023)

Single- and Multiple-Dose Pharmacokinetics and Absolute Bioavailability of Tedizolid
por: Flanagan, Shawn, et al.
Publicado: (2014)

Characteristics of Tedizolid Non-susceptible Enterococcal Clinical Isolates
por: Dhand, Abhay, et al.
Publicado: (2017)

Effect of the human endotoxin challenge on tedizolid tissue penetration
por: Jorda, Anselm, et al.
Publicado: (2022)

471. Safety and Efficacy of Oral and/or Intravenous Tedizolid Phosphate (TZD) in Adolescents with Acute Bacterial Skin and Skin Structure Tissue Infections (ABSSSI)
por: Bradley, John S, et al.
Publicado: (2019)

Pharmacokinetics of Tedizolid and Pseudoephedrine Administered Alone or in Combination in Healthy Volunteers
por: Flanagan, Shawn, et al.
Publicado: (2018)

In Vitro Activity of Tedizolid, Dalbavancin, and Ceftobiprole Against Clostridium difficile
por: Binyamin, Dana, et al.
Publicado: (2018)

Is there a role for tedizolid in the treatment of non-tuberculous mycobacterial disease?
por: Ruth, Mike Marvin, et al.
Publicado: (2020)

Prolonged tedizolid use in cutaneous non-tuberculous mycobacterial infection
por: Shaw, Timothy David, et al.
Publicado: (2021)

Efficacy and Safety of Tedizolid Phosphate versus Linezolid in a Randomized Phase 3 Trial in Patients with Acute Bacterial Skin and Skin Structure Infection
por: Lv, Xiaoju, et al.
Publicado: (2019)

1627. Tedizolid is Well-tolerated Among Patients Receiving Prolonged Treatment Courses, Including Those Who are Intolerant of Alternative Agents
por: Smith, Brandon, et al.
Publicado: (2020)

Tedizolid-Cyclodextrin System as Delayed-Release Drug Delivery with Antibacterial Activity
por: Paczkowska-Walendowska, Magdalena, et al.
Publicado: (2020)

1289. Assessing the Safety and Efficacy with Prolonged Use of Tedizolid in Orthopedic Patients
por: Garza, Daniel E, et al.
Publicado: (2023)

Long-Acting Lipoglycopeptides: “Lineless Antibiotics” for Serious Infections in Persons Who Use Drugs
por: Morrisette, Taylor, et al.
Publicado: (2019)

Efficacy, safety, tolerability and population pharmacokinetics of tedizolid, a novel antibiotic, in Latino patients with acute bacterial skin and skin structure infections
por: Ortiz-Covarrubias, Alejandro, et al.
Publicado: (2016)

Five-year analysis of the in vitro activity of tedizolid against a worldwide collection of indicated species causing clinical infections: results from the Surveillance of Tedizolid Activity and Resistance (STAR) programme
por: Carvalhaes, Cecilia G, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_k7p9m45q9rc70m23u73kova1gk